This trial will explore the effects of a drug on post-COVID POTS symptoms, and evaluate its safety, effectiveness, and more.
- Postural Orthostatic Tachycardia Syndrome (POTS)
2 Primary · 4 Secondary · Reporting Duration: Up to 31 weeks
2 Treatment Groups
1 of 2
1 of 2
42 Total Participants · 2 Treatment Groups
Primary Treatment: Efgartigimod · Has Placebo Group · Phase 2
Who is running the clinical trial?
Age 18+ · All Participants · 0 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Frequently Asked Questions
Has the FDA sanctioned Efgartigimod for commercial availability?
"Our evaluators concluded that Efgartigimod received a safety rating of 2 due to the availability of some data indicating its safety, but not yet having any evidence demonstrating clinical efficacy." - Anonymous Online Contributor
How many enrollees has this clinical experiment attracted thus far?
"Affirmative. Evidence on clinicaltrials.gov demonstrates that this trial, which was initially posted in September 23rd 2022, is still looking for participants. 42 individuals must be recruited from 1 medical site to complete the research." - Anonymous Online Contributor
Is this trial recruiting participants at the moment?
"Affirmative. According to clinicaltrials.gov, the trial which was first posted on September 23rd 2022 is currently seeking participants. 42 subjects need to be recruited from a single medical facility for this study." - Anonymous Online Contributor